Imatinib Mesylate Tablet, Film Coated
Product Images NDC 60687-882

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 60687-882). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100 mg Imatinib Mesylate Tablet Blister (100 mg Imatinib Mesylate Tablet Blister)

Label for Imatinib Mesylate 100 mg film-coated tablets, manufactured by American Health Packaging, Columbus, OH. The label includes medication name, dosage strength, tablet form, lot number 1234567, expiration date 2024-12-24, and two barcodes. Multiple identical label strips are shown in the image.*

FDA Label Image

100 mg Imatinib Mesylate Tablets Carton (100 mg Imatinib Mesylate Tablets Carton)

Imatinib Mesylate 100 mg film-coated tablets in a 30-count package (3 blister packs of 10 tablets each) labeled for oral use. The label includes a barcode, storage instructions, dosage caution, and distributor information for American Health Packaging, Columbus, Ohio. The product is prescription only.*

FDA Label Image

Ahp88221

Imatinib Mesylate 100 mg film-coated tablet, round and orange in color. One side is imprinted with "APO" and the other side has a score line with "IMA" above and "100" below the line. This oral tablet is manufactured by American Health Packaging.*

FDA Label Image

Figure 1: Progression Free Survival (itt Principle) (Figure1)

A Kaplan-Meier survival curve depicting the percentage of patients without disease progression over 72 months since randomization. Two treatment arms: Imatinib Mesylate arm (solid line) and IFN+Ara-C arm (dashed line). The graph includes patient counts by category, hazard ratio with confidence interval, and a log-rank test p-value.*

FDA Label Image

Figure 2: Time To Progression To Ap Or Bc (itt Principle) (Figure2)

A Kaplan-Meier survival curve depicting the percentage of patients without progression to accelerated phase or blast crisis (AP/BC) over 72 months since randomization. The graph compares two treatment arms: Imatinib Mesylate (solid line) and IFN+Ara-C (dashed line). It includes patient numbers, hazard ratio (0.474), and log-rank test significance (P<0.001).*

FDA Label Image

Figure 3: Study 1 Recurrence-free Survival (itt Population) (Figure3)

A Kaplan-Meier survival curve chart comparing the probability of being alive and recurrence-free over time in months for Imatinib 400 mg versus placebo. The X-axis shows survival time in months up to 108, and the Y-axis shows the probability from 0 to 1. The chart includes censored data points for both treatment groups. Patient risk counts are given at various time points.*

FDA Label Image

Figure 4: Study 2 Recurrence-free Survival (itt Population) (Figure4)

A Kaplan-Meier survival curve graph showing the probability of recurrence-free survival over time in months. Two lines compare Imatinib treatment durations of 12 months and 36 months, with corresponding event and censored observation markers. Statistical data including hazard ratio, confidence intervals, and p-value are displayed, along with a table of at-risk subjects and events over time.*

FDA Label Image

Figure 5: Study 2 Overall Survival (itt Population) (Figure5)

A Kaplan-Meier survival curve chart showing the probability of overall survival over time in months for two groups treated with Imatinib Mesylate at 12 months and 36 months. The chart includes survival curves, censored observations, and a statistical summary with hazard ratio and confidence interval.*

FDA Label Image

Structural Formula (Structural Formula)

Chemical structure diagram of Imatinib Mesylate depicting its molecular components including aromatic rings, nitrogen atoms, and the mesylate group with sulfur, oxygen, and methyl groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.